AI Article Synopsis
- Bariatric surgery, specifically sleeve gastrectomy (SG), causes bone loss, but the exact mechanisms remain unclear.
- A study on 83 obesity patients tracked changes in bone mineral density (aBMD) and bone turnover markers at 1, 12, and 24 months post-surgery.
- Findings indicated that bone turnover increased over time, with a significant decrease in aBMD primarily observed in the hip region, attributed mainly to weight loss rather than changes in specific biological markers like periostin, sclerostin, and semaphorin 4D.
Article Abstract
Bariatric surgery induces bone loss, but the exact mechanisms by which this process occurs are not fully known. The aims of this 2-year longitudinal study were to (i) investigate the changes in areal bone mineral density (aBMD) and bone turnover markers following sleeve gastrectomy (SG) and (ii) determine the parameters associated with the aBMD variations. Bone turnover markers, sclerostin, periostin and semaphorin 4D were assessed before and 1, 12 and 24 months after SG, and aBMD was determined by DXA at baseline and after 12 and 24 months in 83 patients with obesity. Bone turnover increased from 1 month, peaked at 12 months and remained elevated at 24 months. Periostin and sclerostin presented only modest increases at 1 month, whereas semaphorin 4D showed increases only at 12 and 24 months. A significant aBMD decrease was observed only at total hip regions at 12 and 24 months. This demineralisation was mainly related to body weight loss. In summary, reduced aBMD was observed after SG in the hip region (mechanical-loading bone sites) due to an increase in bone turnover in favour of bone resorption. Periostin, sclerostin and semaphorin 4D levels varied after SG, showing different time lags, but contrary to weight loss, these biological parameters did not seem to be directly implicated in the skeletal deterioration.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10610316 | PMC |
| http://dx.doi.org/10.3390/nu15204310 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Metabolomic and transcriptomic remodeling of bone marrow myeloid cells in response to maternal obesity.
Am J Physiol Endocrinol Metab
January 2025
Knight Cardiovascular Institute, Oregon Health & Science University, Portland, OR, 97239.
Maternal obesity puts the offspring at high risk of developing obesity and cardio-metabolic diseases in adulthood. Here, we utilized a mouse model of maternal high-fat diet (HFD)-induced obesity that recapitulates metabolic perturbations seen in humans. We show increased adiposity in the offspring of HFD-fed mothers (Off-HFD) when compared to the offspring regular diet-fed mothers (Off-RD).
View Article and Find Full Text PDFBone Turnover Markers Predict Changes in Bone Mineral Density in Men Treated with Abaloparatide: Results from ATOM.
J Bone Miner Res
January 2025
Radius Health Inc, Boston, MA, United States.
Early increases in bone turnover markers (BTMs) in response to anabolic therapy correlate with 18-month bone mineral density (BMD) increases in postmenopausal women with osteoporosis; however, this relationship has not been assessed in men. In this analysis, the correlation between changes from baseline in fasting intact serum procollagen type I N propeptide (PINP) and serum carboxy-terminal cross-linking telopeptide of type I collagen (CTX) at 1, 3, 6, and 12 months and percent increase from baseline in BMD at 12 months in men from the randomized phase 3 ATOM study (NCT03512262) were evaluated using Pearson's correlation coefficients. The uncoupling index (UI), a measure of the balance between markers of bone formation (PINP) and bone resorption (CTX), with positive UI favoring bone formation, was calculated.
View Article and Find Full Text PDFImpact of Platelet-rich Plasma and Platelet-rich Fibrin in Mandibular Third Molar Extraction: A Systematic Review.
J Contemp Dent Pract
September 2024
Department of Periodontology, Narsinhbhai Patel Dental College and Hospital, Sankalchand Patel University, Visnagar, Gujarat, India.
Aim: This study aims to evaluate the impact of platelet-rich fibrin (PRF) and platelet-rich plasma (PRP) on pain, swelling, trismus, soft tissue healing and bone regeneration following mandibular third molar extraction.
Material And Methods: A systematic review was conducted from a period of January 2014 to June 2024 using PRISMA guidelines. The search strategy included databases such as Scopus, PubMed, Google Scholar, and Cochrane Central Register of Controlled Trials, using key terms related to "PRF", "PRP", oral surgery, and third molars.
Increasing Bone Regeneration in Maxillary Sinus Augmentation Using Platelet-rich Fibrin: An Interventional Pre-Post Study.
J Contemp Dent Pract
September 2024
Department of Pediatrics Dentistry and Orthodontics, Faculty Odonto-Stomatology, Can Tho University of Medicine and Pharmacy, Can Tho City, Vietnam.
Aim: This study aimed to evaluate the impact of a combination of immediate implant placement with maxillary sinus augmentation (MSA) solely using platelet-rich fibrin (PRF) on guided bone regeneration.
Materials And Methods: An interventional before-after (pre-post) study design was used with 30 dental patients (≥18 years of age; 14 males and 16 females) with initial bone heights ranging between 4 and 6 mm. Following the general check-up and the creation of a study model, the planned implant location demonstrated an external right maxilla diameter of more than 5 mm, thereby validating the cone-beam computed tomography (CBCT) radiograph.
Signaling Dynamics in Osteogenesis: Unraveling Therapeutic Targets for Bone Generation.
Curr Drug Targets
January 2025
Department of Molecular Medicine, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, Jupiter, FL33458, United States.
Diseases affecting bone encompass a spectrum of disorders, from prevalent conditions such as osteoporosis and Paget's disease, collectively impacting millions, to rare genetic disorders including Fibrodysplasia Ossificans Progressiva (FOP). While several classes of drugs, such as bisphosphonates, synthetic hormones, and antibodies, are utilized in the treatment of bone diseases, their efficacy is often curtailed by issues of tolerability and high incidence of adverse effects. Developing therapeutic agents for bone diseases is hampered by the fact that numerous pathways regulating bone metabolism also perform pivotal functions in other organ systems.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!